Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term combination therapy. Found 10 abstracts

Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Chih-Hsin Yang J, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller SM, Gandhi L. 24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Thorac Oncol. 2019 Jan;14(1):124-9.
Gettinger S, Hellmann MD, Chow LQ, Borghaei H, Antonia S, Brahmer JR, Goldman JW, Gerber DE, Juergens RA, Shepherd FA, Laurie SA, Young TC, Li X, Geese WJ, Rizvi N. Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. J Thorac Oncol. 2018 Sep;13(9):1363-72.
Landau H, Pandit-Taskar N, Hassoun H, Cohen A, Lesokhin A, Lendvai N, Drullinsky P, Schulman P, Jhanwar S, Hoover E, Bello C, Riedel E, Nimer SD, Comenzo RL. Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. Leukemia & lymphoma. 2012 Feb;53(2):275-81.
van Vlerken LE, Duan ZF, Little SR, Seiden MV, Amiji MM. Augmentation of Therapeutic Efficacy in Drug-Resistant Tumor Models Using Ceramide Coadministration in Temporal-Controlled Polymer-Blend Nanoparticle Delivery Systems. Aaps Journal. 2010 Jun;12(2):171-80.   PMCID: PMC2844507 [Available on 2011/2/9]
Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 2009 Nov;115(2):215-20.
Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Selective Raf inhibition in cancer therapy. Expert Opinion on Therapeutic Targets. 2007 Dec;11(12):1587-609.
Chen Y, Weeks RS, Burns MR, Boorman DW, Klein-Szanto A, O'Brien TG. Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma. International journal of cancer. 2006 May;118(9):2344-9.
Zhu Y, Cullen JM, Aldrich CE, Saputelli J, Miller D, Seeger C, Mason WS, Jilbert AR. Adenovirus-based gene therapy during clevudine treatment of woodchucks chronically infected with woodchuck hepatitis virus. Virology. 2004 Sep 13;327(1):26-40.
Krigel RL, Padavicshaller K, Toomey C, Comis RL, Weiner LM. Phase-I Study of Sequentially Administered Recombinant Tumor- Necrosis-Factor and Recombinant Interleukin-2. Journal of Immunotherapy. 1995 Apr;17(3):161-70.
Martenson JA, Lipsitz SR, Lefkopoulou M, Engstrom PF, Dayal YY, Cobau CD, Oken MM, Haller DG. Results of Combined-Modality Therapy for Patients with Anal Cancer (E7283) - an Eastern-Cooperative-Oncology-Group-Study. Cancer. 1995 Nov 15;76(10):1731-6.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term combination therapy

combination therapy cancer chemotherapy bortezomib management induced radiation polyamine transport radiation-therapy CELL LUNG-CANCER factor-alpha hydrophobic drugs Multiple myeloma EGFR-mutant NSCLC PD-1 axis inhibitor recombinant adenoviruses 5132 CGP 69846A trial survival rate Bortezomib advanced cancer nonsquamous non invitro mice lenalidomide targeted delivery kinase inhibitor irradiation erlotinib cells resistance growth-factor refractory multiple-myeloma renal chemotherapeutic-agents therapy squamous-cell carcinoma ornithine decarboxylase clevudine nivolumab MEK modulation Proteosome inhibition antitumor-activity dose interleukin-2 cell-death tumors glucosylceramide growth PHASE-II TRIAL refractory B-Raf C-RAF hepatitis B virus sequential therapy IFN-alpha ph-sensitive system cyto-toxicity ANTITUMOR-ACTIVITY transduction anus transgenic mice pembrolizumab intracellular ceramide modulation apoptosis multidrug-resistance PAPILLARY THYROID-CARCINOMA cytotoxic t-lymphocytes signal tumor necrosis factor alpha-difluoromethylornithine accumulation Ras poly(beta-amino ester) nanoparticles ACUTE temporal-controlled polymeric nanoparticle delivery antiviral therapy proteasome inhibitor intracellular inactivation radiotherapy activated killer cells viral-dna b-virus GROWTH-FACTOR RECEPTOR extramedullary advanced solid tumors ovarian-cancer agent C-RAF-1 c-RAF-1 phase i study small-cell lung cancer Oncology antisense inhibitor gamma-interferon nf-kappa-b regimen closed circular dna systems biology multidrug interleukin-2 malignancy pegylated liposomal doxorubicin MYELOID-LEUKEMIA p-glycoprotein failure skin hepatocyte turnover Ovarian cancer CYSTEINE-RICH DOMAIN ANTISENSE OLIGONUCLEOTIDE epidermal growth factor
Last updated on Thursday, April 02, 2020